Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear …
Over the last 12 months, insiders at Voyager Therapeutics, Inc. have bought $0 and sold $374,797 worth of Voyager Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Voyager Therapeutics, Inc. have bought $20.58M and sold $3.79M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,395,588 shares for transaction amount of $39.03M was made by NEUROCRINE BIOSCIENCES INC (10 percent owner) on 2023‑02‑23.
2025-02-11 | Sale | President & CEO | 16,644 0.0255% | $4.45 | $74,066 | +3.44% | ||
2025-02-11 | Sale | COO & CBO | 6,950 0.0106% | $4.45 | $30,928 | +3.44% | ||
2025-02-11 | Sale | Chief Legal Officer | 4,358 0.0067% | $4.45 | $19,393 | +3.44% | ||
2025-02-11 | Sale | Chief Scientific Officer | 5,413 0.0083% | $4.45 | $24,088 | +3.44% | ||
2025-01-14 | Sale | COO & CBO | 3,087 0.0057% | $5.09 | $15,713 | +5.45% | ||
2025-01-14 | Sale | Chief Scientific Officer | 1,191 0.0022% | $5.13 | $6,110 | +5.45% | ||
2024-12-23 | Sale | COO&CBO | 6,500 0.0117% | $5.65 | $36,725 | -4.89% | ||
2024-10-02 | Sale | Chief Legal Officer | 5,999 0.0109% | $5.82 | $34,914 | +1.63% | ||
2024-04-02 | Sale | President and CEO | 12,115 0.0222% | $9.86 | $119,454 | -30.88% | ||
2024-04-02 | Sale | Chief Operating Officer | 1,357 0.0025% | $9.88 | $13,407 | -30.88% | ||
2024-02-21 | Sale | President and CEO | 13,033 0.0278% | $7.46 | $97,226 | -7.33% | ||
2024-02-21 | Sale | Chief Financial Officer | 3,764 0.008% | $7.46 | $28,079 | -7.33% | ||
2024-02-21 | Sale | Chief Operating Officer | 3,966 0.0084% | $7.45 | $29,547 | -7.33% | ||
2024-02-21 | Sale | Chief Scientific Officer | 3,365 0.0072% | $7.47 | $25,137 | -7.33% | ||
2024-02-20 | Sale | Chief Scientific Officer | 602 0.0013% | $7.68 | $4,623 | -6.21% | ||
2024-01-17 | Sale | Chief Operating Officer | 2,543 0.0054% | $7.15 | $18,182 | +3.42% | ||
2024-01-17 | Sale | Chief Scientific Officer | 1,266 0.0027% | $7.18 | $9,090 | +3.42% | ||
2023-10-03 | Sale | Chief Financial Officer | 13,567 0.0298% | $6.99 | $94,833 | +9.93% | ||
2023-09-15 | Sale | Chief Scientific Officer | 10,500 0.0245% | $8.16 | $85,680 | -2.14% | ||
2023-07-06 | Sale | Chief Scientific Officer | 5,500 0.0137% | $10.80 | $59,400 | -23.12% |
NEUROCRINE BIOSCIENCES INC | 10 percent owner | 8575316 15.6983% | $4.22 | 2 | 0 | +7.14% |
EcoR1 Capital, LLC | director | 3851507 7.0507% | $4.22 | 1 | 3 | +28.87% |
Sanofi | 2477941 4.5362% | $4.22 | 1 | 0 | <0.0001% | |
PAUL STEVEN M | President and CEO | 872351 1.597% | $4.22 | 1 | 0 | <0.0001% |
GERAGHTY JAMES A | director | 76588 0.1402% | $4.22 | 2 | 0 | <0.0001% |
Increased Positions | 70 | +52.24% | 2M | +7.11% |
Decreased Positions | 54 | -40.3% | 3M | -8.35% |
New Positions | 23 | New | 465,537 | New |
Sold Out Positions | 18 | Sold Out | 850,559 | Sold Out |
Total Postitions | 150 | +11.94% | 35M | -1.24% |
Armistice Capital, Llc | $22,825.00 | 9.81% | 5.4M | +196,000 | +3.77% | 2024-12-31 |
Blackrock, Inc. | $22,659.00 | 9.74% | 5.36M | -73,641 | -1.36% | 2024-12-31 |
Ecor1 Capital, Llc | $16,571.00 | 7.12% | 3.92M | 0 | 0% | 2024-12-31 |
Vanguard Group Inc | $13,601.00 | 5.85% | 3.22M | +29,014 | +0.91% | 2024-12-31 |
Farallon Capital Management Llc | $10,874.00 | 4.67% | 2.57M | +278,700 | +12.16% | 2024-12-31 |
Dimensional Fund Advisors Lp | $5,840.00 | 2.51% | 1.38M | +275,571 | +24.94% | 2024-12-31 |
Vestal Point Capital, Lp | $5,203.00 | 2.24% | 1.23M | +740,000 | +151.02% | 2024-12-31 |
Geode Capital Management, Llc | $4,586.00 | 1.97% | 1.08M | +4,729 | +0.44% | 2024-12-31 |
Erste Asset Management Gmbh | $4,477.00 | 1.92% | 1.06M | 0 | 0% | 2024-12-31 |
State Street Corp | $3,811.00 | 1.64% | 900,932 | +8,189 | +0.92% | 2024-12-31 |